Kalaris positive expanded Phase 1a data for TH103 in neovascular AMD

 

Kalaris Therapeutics reports positive expanded Phase 1a data for TH103 in neovascular AMD with sustained efficacy, no intraocular inflammation at 2.5 mg

• Expanded Phase 1a trial used a single-ascending-dose design and evaluated TH103 2.5 mg after process improvements.

https://finviz.com/stock?t=KLRS&p=d